183 related articles for article (PubMed ID: 30660172)
1. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
Rattananukrom T; Svetvilas P; Chanprapaph K
Asian Pac J Allergy Immunol; 2020 Dec; 38(4):286-289. PubMed ID: 30660172
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature.
Degirmentepe EN; Kızıltac K; Etikan P; Singer R; Memet B; Kocaturk E
Ann Dermatol; 2019 Jun; 31(3):335-338. PubMed ID: 33911601
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration.
Ito T; Maeda T; Egusa C; Abe N; Seshimo H; Okubo Y; Harada K
Allergol Int; 2021 Apr; 70(2):269-270. PubMed ID: 33183981
[No Abstract] [Full Text] [Related]
6. Urticarial vasculitis: a unique presentation.
Stigall LE; Sigmon JR; Leicht SS
South Med J; 2009 May; 102(5):531-3. PubMed ID: 19373142
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.
Faisant C; Du Thanh A; Mansard C; Deroux A; Boccon-Gibod I; Bouillet L
J Clin Immunol; 2017 Jan; 37(1):80-84. PubMed ID: 27826875
[TBL] [Abstract][Full Text] [Related]
8. A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab.
Nucera E; Basta F; Buonomo A; Mezzacappa S; Margiotta DP; Antonelli Incalzi R; Schiavino D
J Investig Allergol Clin Immunol; 2017; 27(6):382-384. PubMed ID: 29199964
[No Abstract] [Full Text] [Related]
9. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
[TBL] [Abstract][Full Text] [Related]
10. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
11. Response of omalizumab in normocomplementemic urticarial vasculitis.
Chen YD; Krause K; Tu P; Zhao ZT; Maurer M
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2114-2117.e2. PubMed ID: 32145404
[No Abstract] [Full Text] [Related]
12. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
13. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study.
Bonnekoh H; Jelden-Thurm J; Allenova A; Chen Y; Cherrez-Ojeda I; Danilycheva I; Dorofeeva I; Jardim Criado RF; Criado PR; Gelincik Akkor A; Hawro T; Kocatürk E; Khoshkhui M; Metz M; Nasr I; Steć M; Zhao Z; Aulenbacher F; Salameh P; Altrichter S; Gonçalo M; Gimenez-Arnau A; Maurer M; Krause K; Kolkhir P
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2900-2910.e21. PubMed ID: 37364667
[TBL] [Abstract][Full Text] [Related]
14. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis.
Navarro-Navarro I; Jiménez-Gallo D; Villegas-Romero I; Linares-Barrios M
Dermatol Ther; 2020 Mar; 33(2):e13237. PubMed ID: 32012397
[No Abstract] [Full Text] [Related]
15. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
[No Abstract] [Full Text] [Related]
16. Urticarial Vasculitis Successfully Treated With Omalizumab.
Ermertcan AT; Aktaş A; Öztürk F; Temiz P
Cutis; 2021 May; 107(5):E19-E21. PubMed ID: 34288864
[No Abstract] [Full Text] [Related]
17. Effectiveness of omalizumab in a case of urticarial vasculitis.
Fueyo-Casado A; Campos-Muñoz L; González-Guerra E; Pedraz-Muñoz J; Cortés-Toro JA; López-Bran E
Clin Exp Dermatol; 2017 Jun; 42(4):403-405. PubMed ID: 28247460
[TBL] [Abstract][Full Text] [Related]
18. Cold urticarial vasculitis successfully treated with omalizumab.
Ayén-Rodríguez A; Llamas-Molina JM; Gálvez-Moreno M; Ruiz-Villaverde R
Int J Dermatol; 2023 Feb; 62(2):e77-e78. PubMed ID: 35167707
[No Abstract] [Full Text] [Related]
19. Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic.
Larenas-Linnemann DES; Parisi CAS; Ritchie C; Cardona-Villa R; Cherrez-Ojeda I; Cherrez A; Ensina LF; Garcia E; Medina IV; Rodríguez-González M; Caraballo JMS
Curr Allergy Asthma Rep; 2018 May; 18(5):33. PubMed ID: 29744661
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
